DK2168585T3 - Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf - Google Patents

Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf

Info

Publication number
DK2168585T3
DK2168585T3 DK10000305.2T DK10000305T DK2168585T3 DK 2168585 T3 DK2168585 T3 DK 2168585T3 DK 10000305 T DK10000305 T DK 10000305T DK 2168585 T3 DK2168585 T3 DK 2168585T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
neuroactive steroid
pregnan
methoxymethyl
imidazolyl
Prior art date
Application number
DK10000305.2T
Other languages
English (en)
Inventor
Richard M Woodward
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK2168585T3 publication Critical patent/DK2168585T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10000305.2T 2005-06-09 2006-06-09 Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf DK2168585T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68890505P 2005-06-09 2005-06-09
EP06754274A EP1888080B1 (en) 2005-06-09 2006-06-09 Pharmaceutical compositions of a neuroactive steroid and uses thereof

Publications (1)

Publication Number Publication Date
DK2168585T3 true DK2168585T3 (da) 2012-02-27

Family

ID=36790861

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10000305.2T DK2168585T3 (da) 2005-06-09 2006-06-09 Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
DK06754274.6T DK1888080T3 (da) 2005-06-09 2006-06-09 Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06754274.6T DK1888080T3 (da) 2005-06-09 2006-06-09 Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf

Country Status (26)

Country Link
US (2) US20090131383A1 (da)
EP (3) EP2263675A3 (da)
JP (2) JP2008542419A (da)
KR (3) KR20100095661A (da)
CN (1) CN101193640A (da)
AT (2) ATE538797T1 (da)
AU (1) AU2006256851C1 (da)
BR (1) BRPI0612921A2 (da)
CA (1) CA2611430C (da)
CY (2) CY1110199T1 (da)
DE (1) DE602006013622D1 (da)
DK (2) DK2168585T3 (da)
EA (1) EA013744B1 (da)
ES (2) ES2380060T3 (da)
HK (2) HK1140947A1 (da)
HR (2) HRP20100372T1 (da)
IL (3) IL187813A (da)
NO (1) NO20076319L (da)
NZ (1) NZ562979A (da)
PL (2) PL2168585T3 (da)
PT (2) PT1888080E (da)
RS (2) RS51304B (da)
SI (2) SI1888080T1 (da)
UA (1) UA94909C2 (da)
WO (1) WO2006131392A1 (da)
ZA (1) ZA200709188B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
HUE041369T2 (hu) 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2017005002A (es) * 2014-10-16 2018-01-23 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc.
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス, インコーポレイテッド C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US20200188358A1 (en) * 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression
KR20210105934A (ko) * 2018-12-17 2021-08-27 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN113891715A (zh) * 2019-03-04 2022-01-04 普拉西斯精密医药公司 围绝经期和绝经期的治疗方法
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées
JP2022552808A (ja) * 2019-10-02 2022-12-20 プラクシス プレシジョン メディシンズ, インコーポレイテッド Gaba-a受容体陽性アロステリック調節因子と、nmda拮抗薬、nmda陰性アロステリック調節因子、またはnmda部分作動薬との組み合わせ
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
JP2024506942A (ja) * 2021-02-18 2024-02-15 プラクシス プレシジョン メディシンズ, インコーポレイテッド Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
EP4329751A1 (en) * 2021-04-26 2024-03-06 Praxis Precision Medicines, Inc. Methods of treatment with neuroactive steroids
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
WO2023164386A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4884909A (en) 1986-12-25 1989-12-05 Canon Kabushiki Kaisha Recording apparatus
IL112638A (en) * 1994-02-14 2003-10-31 Cocensys Inc 3alpha-HYDROXYLATED PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
WO2000066614A1 (en) * 1999-04-29 2000-11-09 Purdue Pharma Ltd. 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one

Also Published As

Publication number Publication date
UA94909C2 (ru) 2011-06-25
HK1118202A1 (en) 2009-02-06
IL216194A (en) 2013-09-30
WO2006131392A8 (en) 2007-02-15
ATE538797T1 (de) 2012-01-15
CA2611430A1 (en) 2006-12-14
ZA200709188B (en) 2008-08-27
IL187813A0 (en) 2008-08-07
HRP20100372T1 (hr) 2010-08-31
PL1888080T3 (pl) 2010-09-30
KR20100095661A (ko) 2010-08-31
SI1888080T1 (sl) 2010-08-31
PT1888080E (pt) 2010-07-06
PT2168585E (pt) 2012-03-05
US20120276196A1 (en) 2012-11-01
NZ562979A (en) 2010-11-26
HRP20120264T1 (hr) 2012-04-30
KR20120028407A (ko) 2012-03-22
EP2168585B1 (en) 2011-12-28
AU2006256851B2 (en) 2009-12-17
CY1112499T1 (el) 2015-12-09
EP1888080A1 (en) 2008-02-20
JP2008542419A (ja) 2008-11-27
DK1888080T3 (da) 2010-07-19
IL216194A0 (en) 2012-01-31
ES2344313T3 (es) 2010-08-24
RS51304B (sr) 2010-12-31
BRPI0612921A2 (pt) 2010-12-07
EP2263675A2 (en) 2010-12-22
CY1110199T1 (el) 2015-01-14
NO20076319L (no) 2007-12-07
EP2168585A1 (en) 2010-03-31
ES2380060T3 (es) 2012-05-08
CN101193640A (zh) 2008-06-04
DE602006013622D1 (de) 2010-05-27
AU2006256851A1 (en) 2006-12-14
EA013744B1 (ru) 2010-06-30
EP1888080B1 (en) 2010-04-14
IL187813A (en) 2011-12-29
ATE464054T1 (de) 2010-04-15
AU2006256851C1 (en) 2010-07-15
WO2006131392A1 (en) 2006-12-14
EA200800007A1 (ru) 2008-04-28
EP2263675A3 (en) 2011-05-18
CA2611430C (en) 2013-09-10
RS52199B (en) 2012-10-31
US20090131383A1 (en) 2009-05-21
IL211114A (en) 2014-04-30
PL2168585T3 (pl) 2012-05-31
JP2012229261A (ja) 2012-11-22
KR20080017091A (ko) 2008-02-25
SI2168585T1 (sl) 2012-04-30
HK1140947A1 (en) 2010-10-29

Similar Documents

Publication Publication Date Title
DK1888080T3 (da) Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
WO2004075864A3 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
FR2909284B1 (fr) Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
PT2038290E (pt) Moduladores de receptor do tipo toll 7
TW200626132A (en) Topical nepafenac formulations
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
WO2005094810A3 (en) Novel pharmaceutical compositions
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
DK1750703T3 (da) Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
MX2009003169A (es) Derivados de sulfonamida.
WO2006036981A3 (en) Small molecule modulators of cytokine activity
WO2006004903A3 (en) 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine
CY1117266T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντι-καρκινικοι παραγοντες
TW200740442A (en) Therapeutic agent for hypertension
UA97112C2 (ru) Модуляторы фармакокинетических свойств лекарственных средств